Company intelligence / Profile preview
SporeGen
United Kingdomsporegen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SporeGen is developing heat-stable mucosal vaccines, probiotics, and drug delivery systems based on Bacillus spores, with unique approaches for Clostridioides difficile infection. No published clinical trial results.
- Therapeutic areas
- GastroenterologyOncologyInfectious Diseases
- Modalities
- Live biotherapeutic product therapyVaccineMicrobial therapyDrug delivery system
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Destiny Pharma
Beyond the preview
Go deeper on SporeGen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SporeGen.